Ticker Launch
Sign inTry it free

Reverse merger · Pending · AVZO

Avenzo Therapeutics, Inc.

Reverse merger with Rallybio Corporation (RLYB)

Avenzo Therapeutics, Inc. agreed to merge into Rallybio Corporation (RLYB), a Nasdaq-listed clinical-stage biotech distributing its net cash before the merger, in a reverse merger that takes the private company public. The deal was announced on Jun 1, 2026. The combined company is expected to trade as Avenzo Therapeutics, Inc. (AVZO) on Nasdaq.

Avenzo Therapeutics is an oncology biotechnology company advancing a portfolio of four clinical-stage programs, including small molecules and antibody-drug conjugates, for cancer patients.

Status
Pending
Private company
Avenzo Therapeutics, Inc.
Public company
Rallybio Corporation (RLYB)
Public company business before
Nasdaq-listed clinical-stage biotech distributing its net cash before the merger
Announced
Jun 1, 2026
Combined company
Avenzo Therapeutics, Inc. (AVZO)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending reverse mergers